Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.
, Adam I Kaplin 2, Deepa M Deshpande 1, Carlos A Pardo 1, Douglas A Kerr 11 Department of Neurology, Johns Hopkins Transverse Myelitis Center, 600 N. Wolfe Street Pathology 627C, Baltimore MD 21287-6965
2 Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Osler 320, 600 N. Wolfe Street, Baltimore, MD 21287-5371
Abstract
Transverse Myelitis (TM) is a clinical syndrome in which an immune-mediated process causes neural injury to the spinal cord, resulting in varying degrees of weakness, sensory alterations and autonomic dysfunction. TM may exist as part of a multi-focal CNS disease (e.g. MS), multi-systemic disease (e.g. systemic lupus erythematosus), or as an isolated, idiopathic entity. In this article, we will summarize recent classification and diagnostic schemes (1), which provide a framework for the acute management of patients with TM. Additionally, we will review current concepts on the natural history, immunopathogenesis and treatment strategies for patients with TM.
Keywords
- Transverse myelopathy
- Transverse myelitis
- Neuroimmunologic disorders
- Interleukin-6
- Review